DIMERIX LIMITED (DXB)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

DXB

DXB - DIMERIX LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.01
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.56

12 Jun
2025

0.020

OPEN

$0.54

3.70%

HIGH

$0.56

1,045,060

LOW

$0.54

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-3.8
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.4 M
Book Value Per Share xxxxxxxxxxxxxxx3.3
Net Operating Cash Flow xxxxxxxxxxxxxxx-7.2 M
Net Profit Margin xxxxxxxxxxxxxxx-4,190.55 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-141.42 %
Return on Invested Capital xxxxxxxxxxxxxxx-141.01 %
Return on Assets xxxxxxxxxxxxxxx-68.53 %
Return on Equity xxxxxxxxxxxxxxx-141.42 %
Return on Total Capital xxxxxxxxxxxxxxx-166.81 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-7.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx22 M
Price To Book Value xxxxxxxxxxxxxxx15.43

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx3.88 %
Cost of Goods Sold xxxxxxxxxxxxxxx-
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx26 M
Research & Development xxxxxxxxxxxxxxx21 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Petra Capital

04/06/2025

1

Buy

$1.58

182.14%

Dimerix has an exclusive development and license agreement with Japan’s Fuso Pharmaceutical Industries, struck in January 2025, for the commercialisation of its lead drug candidate DMX-200 in Japan.

Initiation of the first clinical site for the Action3 Phase 3 trial in Japan has triggered an around $4.3m milestone payment to Dimerix from Fuso.

Fuso will fund all trial-related costs in Japan, where around 20 patients are to be enrolled as part of the global 286-patient study evaluating DMX-200 in Focal Segmental Glomerulosclerosis (FSGS).

The total deal with Fuso is valued at circa $107m, explains the broker, including up to $30.6m in development milestones, $69.4m in commercial milestones, and 15-20% royalties on sales.

Petra highlights the additional Japanese recruitment should accelerate trial enrolment, with 191 patients dosed as of May 19 and full recruitment targeted for 4Q of 2025.

The broker maintains a Buy rating and a $1.58 target price.

FORECAST
Petra Capital forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -3.60 cents.
Petra Capital forecasts a full year FY26 dividend of 0.00 cents and EPS of 2.70 cents.
Access Extra Coverage Research History >

DXB STOCK CHART

FNArena News on DXB

1
Australian Broker Call *Extra* Edition – Jun 04, 2025

Jun 04 2025 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – May 08, 2025

May 08 2025 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – May 07, 2025

May 07 2025 - Daily Market Reports
4
Next Week At A Glance – 5-9 May 2025

May 02 2025 - Weekly Reports
5
Australian Broker Call *Extra* Edition – May 01, 2025

May 01 2025 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View
2
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
3
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
4
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
5
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
6
CSL Shares Breaking Free

Jul 23 2024 - Technicals
7
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
8
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
9
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
10
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps